SCHEMBL2193301

SCHEMBL2193301

Nc1nc2ccc(OCc3ccccc3)nc2n1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR1A P08908 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
PDE10A Q9Y233 1/20 0.43
CYP3A4 P08684 1/20 0.41
HCAR1 Q9BXC0 1/20 0.41
RAB9A P51151 4/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
NPC1 O15118 3/20 0.40
MAOB P27338 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
MAOA P21397 1/20 0.40
NUDT1 P36639 1/20 0.39
PKM P14618 3/20 0.39
ADORA1 P30542 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195967 0.91 HCAR1 (0.41) HTR3EHTR3BHTR1AHTR3AHTR3D
SCHEMBL2219748 0.81 HCAR1 (0.44) HTR3EHTR3BHTR1AHTR3AHTR3D
SCHEMBL16084159 0.79 HTR3E (0.42) HTR3EHTR3BHTR1AHTR3AHTR3D
SCHEMBL2194786 0.75 PDE10A (0.70) HTR3EHTR3BHTR1AHTR3AHTR3D
SCHEMBL2194398 0.74 HCAR1 (0.43) HTR3EHTR3BHTR1AHTR3AHTR3D
SCHEMBL2194695 0.72 HCAR1 (0.48) HCAR1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL2262510 0.72 PDE7A (0.41) PDE10ARAB9AL3MBTL1NPC1PKM
SCHEMBL2223214 0.72 HCAR1 (0.43) HTR3EHTR3BHTR1AHTR3AHTR3D
SCHEMBL31068655 0.70 PDE10A (0.48) HTR3EHTR3BHTR1AHTR3AHTR3D
SCHEMBL5778685 0.70 AKT1 (0.51) HCAR1MAPTPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 HTR3E 680/4885HTR3B 551/4885HTR1A 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.